NMR Research Unit, Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, UK; MS Centre of Catalonia (Cemcat), Vall d'Hebron Institute of Research, Vall d'Hebron Barcelona Hospital Campus, Spain.
NMR Research Unit, Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, UK; Radiomics Group, Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Neuroimage Clin. 2022;33:102904. doi: 10.1016/j.nicl.2021.102904. Epub 2021 Dec 2.
Predicting disability in progressive multiple sclerosis (MS) is extremely challenging. Although there is some evidence that the spatial distribution of white matter (WM) lesions may play a role in disability accumulation, the lack of well-established quantitative metrics that characterise these aspects of MS pathology makes it difficult to assess their relevance for clinical progression. This study introduces a novel approach, called SPACE-MS, to quantitatively characterise spatial distributional features of brain MS lesions, so that these can be assessed as predictors of disability accumulation. In SPACE-MS, the covariance matrix of the spatial positions of each patient's lesional voxels is computed and its eigenvalues extracted. These are combined to derive rotationally-invariant metrics known to be common and robust descriptors of ellipsoid shape such as anisotropy, planarity and sphericity. Additionally, SPACE-MS metrics include a neuraxis caudality index, which we defined for the whole-brain lesion mask as well as for the most caudal brain lesion. These indicate how distant from the supplementary motor cortex (along the neuraxis) the whole-brain mask or the most caudal brain lesions are. We applied SPACE-MS to data from 515 patients involved in three studies: the MS-SMART (NCT01910259) and MS-STAT1 (NCT00647348) secondary progressive MS trials, and an observational study of primary and secondary progressive MS. Patients were assessed on motor and cognitive disability scales and underwent structural brain MRI (1.5/3.0 T), at baseline and after 2 years. The MRI protocol included 3DT1-weighted (1x1x1mm) and 2DT2-weighted (1x1x3mm) anatomical imaging. WM lesions were semiautomatically segmented on the T2-weighted scans, deriving whole-brain lesion masks. After co-registering the masks to the T1 images, SPACE-MS metrics were calculated and analysed through a series of multiple linear regression models, which were built to assess the ability of spatial distributional metrics to explain concurrent and future disability after adjusting for confounders. Patients whose WM lesions laid more caudally along the neuraxis or were more isotropically distributed in the brain (i.e. with whole-brain lesion masks displaying a high sphericity index) at baseline had greater motor and/or cognitive disability at baseline and over time, independently of brain lesion load and atrophy measures. In conclusion, here we introduced the SPACE-MS approach, which we showed is able to capture clinically relevant spatial distributional features of MS lesions independently of the sheer amount of lesions and brain tissue loss. Location of lesions in lower parts of the brain, where neurite density is particularly high, such as in the cerebellum and brainstem, and greater spatial spreading of lesions (i.e. more isotropic whole-brain lesion masks), possibly reflecting a higher number of WM tracts involved, are associated with clinical deterioration in progressive MS. The usefulness of the SPACE-MS approach, here demonstrated in MS, may be explored in other conditions also characterised by the presence of brain WM lesions.
预测进行性多发性硬化症(MS)的残疾情况极具挑战性。尽管有证据表明,脑白质(WM)病变的空间分布可能在残疾累积中发挥作用,但缺乏能够对 MS 病理学的这些方面进行特征描述的既定定量指标,使得评估其对临床进展的相关性变得十分困难。本研究引入了一种新方法,称为 SPACE-MS,用于对脑 MS 病变的空间分布特征进行定量描述,以便将其评估为残疾累积的预测因子。在 SPACE-MS 中,计算每个患者病变体素的空间位置的协方差矩阵,并提取其特征值。这些特征值组合在一起,得出旋转不变的度量标准,这些标准通常是椭球形状的常见且稳健描述符,例如各向异性、平面性和球形度。此外,SPACE-MS 度量标准还包括神经轴尾端指数,我们为全脑病变掩模以及最尾端脑病变定义了该指数。这表明从补充运动皮质(沿着神经轴)有多远,全脑掩模或最尾端脑病变就有多远。我们将 SPACE-MS 应用于三项研究中的 515 名患者的数据:MS-SMART(NCT01910259)和 MS-STAT1(NCT00647348)二级进展性 MS 试验,以及原发性和继发性进展性 MS 的观察性研究。患者在基线和 2 年后接受了运动和认知残疾量表评估,并接受了结构脑 MRI(1.5/3.0T)检查。MRI 方案包括 3DT1 加权(1x1x1mm)和 2DT2 加权(1x1x3mm)解剖成像。在 T2 加权扫描上半自动分割 WM 病变,得出全脑病变掩模。在将掩模配准到 T1 图像后,计算 SPACE-MS 度量标准,并通过一系列多元线性回归模型进行分析,这些模型用于评估空间分布度量标准在调整混杂因素后解释同时期和未来残疾的能力。在基线时,WM 病变沿神经轴更尾端或在脑内分布更各向同性的患者(即全脑病变掩模显示出较高的球形度指数),其基线和随时间推移的运动和/或认知残疾更大,这与脑病变负荷和萎缩测量无关。总之,我们在这里介绍了 SPACE-MS 方法,我们表明它能够独立于病变和脑组织丢失的数量捕捉到具有临床意义的 MS 病变的空间分布特征。位于神经纤维密度特别高的脑下部(如小脑和脑干)的病变位置,以及病变空间扩散(即更各向同性的全脑病变掩模)更大,可能反映出涉及的 WM 束数量更多,与进展性 MS 的临床恶化有关。在 MS 中证明的 SPACE-MS 方法的有用性可能会在其他也以脑 WM 病变为特征的疾病中进行探索。